Kraft Heinz enters into distribution partnership with Indo Nissin Foods
Post the successful completion of the sale of its non-core Indian brands Complan, Glucon-D, Nycil and Sampriti to Zydus Cadila, Kraft Heinz has now e06-02-2019
06-02-2019
Cadila Healthcare Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
The Company has planned investor interaction through a conference call on February 7, 2019 at 4:00 p.m., post announcement of unaudited financial results for the quarter / nine months ended on December 31, 2018.02-02-2019
CADILA HEALTHCARE LTD. - 532321 - Disclosure Under Reg. 29(2) Of SEBI SAST Regulations, 2015
Disclosure under Reg. 29(2) of SEBI SAST Regulations, 201531-01-2019
Cadila Healthcare Ltd - 532321 - Board Meeting Intimation for To Approve Unaudited Financial Results
CADILA HEALTHCARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 07/02/2019 ,inter alia, to consider and approve The meeting of the Board of Directors of the Company will be held on Thursday, February 7, 2019 to consider apart from other agenda items to approve the unaudited financial results for the quarter / nine months ended on December 31, 2018. Further, as per code of conduct for prevention of Insider Trading adopted by the Company under SEBI [Prohibition of Insider Trading] Regulations, 2015, the Trading Window will remain closed from January 27, 2019 to February 10, 2019 for all Directors and Designated Officers of the Company.24-01-2019
Zydus Cadila gets tentative USFDA nod for generic acid-reflux drug
Drug firm Zydus Cadila on Monday said it has received tentative approval from the US health regulator to market generic Esomeprazole Magnesium delaye21-01-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives tentative approval from the USFDA for Esomeprazole Magnesium Delayed-Release Capsules USP21-01-2019
CADILA HEALTHCARE LTD. - 532321 - Statement Of Investor Complaints For The Quarter Ended December 2018
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0541 Name of the Signatory :- Upen ShahDesignation :- Company Secretary and Compliance Officer18-01-2019
Zydus Cadila gets USFDA nod for Acetazolamide ER capsules
These capsules are used to treat certain types of glaucoma and prevent altitude sickness17-01-2019
CADILA HEALTHCARE LTD. - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Zydus receives final approval from the USFDA for Acetazolamide ER Capsules17-01-2019